GlassScriptPhysician profile
Kinnari Kennedy
NPI 1952763435
$4,953.15
in general payments reported to CMS, 2019-2025
34 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $203 · 2021: $575 · 2022: $241 · 2023: $1,560 · 2024: $913 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Travel and Lodging: $456 · Education: $89.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.07 |
| Travel and Lodging | $455.83 |
| Education | $89.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,318.32 | 2021-2024 | Axonics, Bulkamid |
| Medtronic USA, INC. | $701.50 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $346.60 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $339.98 | 2021-2025 | |
| Janssen Biotech, INC. | $284.59 | 2022-2025 | Erleada |
| Coloplast Corp | $260.82 | 2023-2025 | Speedicath |
| Astellas Pharma US INC | $176.80 | 2021-2024 | Myrbetriq, Xtandi |
| Neotract INC. | $164.22 | 2019 | |
| Abbvie INC. | $154.06 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $132.14 | 2023-2025 | Pylarify |
| Boston Scientific Corporation | $101.28 | 2019-2025 | Axonics, Solyx Sis System |
| Antares Pharma, INC. | $82.87 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $81.40 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $77.10 | 2024-2025 | Adstiladrin |
| Baxter Healthcare | $75.87 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $70.21 | 2023 | |
| Tolmar, INC. | $60.08 | 2023-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $56.18 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Laborie Medical Technologies Corp. | $46.22 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Urovant Sciences INC | $44.49 | 2022 | |
| Urogen Pharma, INC. | $41.32 | 2025 | |
| Procept Biorobotics Corporation | $39.67 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Allergan, INC. | $38.11 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $34.78 | 2024 | |
| Bioprotect Medical, INC. | $33.65 | 2024 | Bioprotect Balloon Implant System |
| Photocure INC | $30.84 | 2022 | |
| Tempus Ai, INC | $29.83 | 2024 | |
| Blue Earth Diagnostics | $25.51 | 2021 | |
| Abbott Laboratories | $21.62 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.14 | 2021 | |
| Accord Healthcare, INC. | $16.92 | 2024 | |
| Dentsply Ih Ab | $16.38 | 2025 | Lofric |
| Clarus Therapeutics INC. | $15.79 | 2021 | |
| Teleflex LLC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinnari Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.